Dr. Reddy’s Labs signs deal worth up to $150m to sell E7777 rights to Citius
Dr. Reddy's Laboratories (Dr. Reddy's Labs) has agreed to divest its rights to E7777, an engineered IL-2-diphtheria toxin fusion protein, and certain related assets to ... Read More
Citius seeks FDA nod for evaluating stem cell therapy for ARDS in COVID-19
Citius Pharmaceuticals has made a Pre-IND submission to the US Food and Drug Administration for a novel stem cell therapy for acute respiratory distress syndrome ... Read More
Citius Pharmaceuticals expands scientific advisory board to enhance focus on infectious disease treatments
Citius Pharmaceuticals, a specialty pharmaceutical company based in New Jersey, has announced the addition of Dr. Lawrence Mermel to its Scientific Advisory Board (SAB). Dr. ... Read More